ERBB2 and breast carcinoma: Sensitivity analyses treating AR as a continuous variable showed directionally consistent but non-significant results.<h4>Conclusions</h4>AR expression may have prognostic value in ER+/HER2- breast cancer, particularly for DFS and in selected patients with residual disease after neoadjuvant chemotherapy.